Xavier Montalban, M.D., Ph.D., from the Vall d’Hebron University Hospital in Barcelona, Spain, and colleagues conducted a randomized phase 2 trial involving patients with relapsing multiple sclerosis. A total of 267 patients were randomly assigned to one of five groups: placebo, evobrutinib (at doses of 25 mg once daily, 75 mg once daily, or 75 mg twice daily),...